February 01, 2015

Leading Animal Health Company, Boehringer Ingelheim Vetmedica, Inc., Announces Website Redesign

Redesigned Bi-vetmedica.com Features Mobile-ready Options, Online Research and Catalog of Scientific Publications by Knowledge Leaders

Today, Boehringer Ingelheim Vetmedica, Inc. (BIVI), the 5th largest animal health company in the United States, announces the launch of its redesigned platform forwww.bi-vetmedica.com.  

The redesigned site presents information on the Company, products and technology and information on BIVI’s corporate responsibility program, BIVI Giving Well.  The site offers visitors valuable resources on the animal health industry and information on industry partnerships and programs that BIVI is involved.Additionally, the revitalized site is adaptive for mobile users.

“The goal of the new website was to improve site navigation and experience, for customers and employees who are looking for information ranging from the products we manufacture to the job opportunities that are available in our growing U.S. business,” says Tim Bettington, vice president of sales and marketing, BIVI.

Bettington continues, "The redesign reflects the level of professionalism and strong commitment to quality that BIVI is respected and recognized for globally. The experience doesn’t end here. We plan to add additional resources, information and tools to the website in 2015.”

About Boehringer Ingelheim

Boehringer Ingelheim Vetmedica, Inc., (BIVI) is a leader in the animal health industry with its portfolio of innovative vaccine and pharmaceutical solutions for the prevention and treatment of disease within the swine, cattle, equine and pet markets. BIVI is the U.S. division of the global Boehringer Ingelheim Animal Health GmbH. Our U.S. headquarters are located within the KC Animal Health Corridor in St. Joseph, Mo., with other sites in Ames, Fort Dodge and Sioux Center, Iowa.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates and more than 47,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is a central element of Boehringer Ingelheim’s culture. Involvement in social projects, caring for the employees and their families and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors of all Boehringer Ingelheim’s endeavors.

With nearly 3,000 employees worldwide, Boehringer Ingelheim Animal Health achieved net sales of about $1.46 billion (1.07 billion euros) in 2013. In our research-driven Animal Health business, Boehringer Ingelheim continually invests more than 10% of net sales of the Animal Health business in R&D.